» Articles » PMID: 33872312

The Landscape of Metabolic Pathway Dependencies in Cancer Cell Lines

Overview
Specialty Biology
Date 2021 Apr 19
PMID 33872312
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The metabolic reprogramming of cancer cells creates metabolic vulnerabilities that can be therapeutically targeted. However, our understanding of metabolic dependencies and the pathway crosstalk that creates these vulnerabilities in cancer cells remains incomplete. Here, by integrating gene expression data with genetic loss-of-function and pharmacological screening data from hundreds of cancer cell lines, we identified metabolic vulnerabilities at the level of pathways rather than individual genes. This approach revealed that metabolic pathway dependencies are highly context-specific such that cancer cells are vulnerable to inhibition of one metabolic pathway only when activity of another metabolic pathway is altered. Notably, we also found that the no single metabolic pathway was universally essential, suggesting that cancer cells are not invariably dependent on any metabolic pathway. In addition, we confirmed that cell culture medium is a major confounding factor for the analysis of metabolic pathway vulnerabilities. Nevertheless, we found robust associations between metabolic pathway activity and sensitivity to clinically approved drugs that were independent of cell culture medium. Lastly, we used parallel integration of pharmacological and genetic dependency data to confidently identify metabolic pathway vulnerabilities. Taken together, this study serves as a comprehensive characterization of the landscape of metabolic pathway vulnerabilities in cancer cell lines.

Citing Articles

Unveiling prognostic value of JAK/STAT signaling pathway related genes in colorectal cancer: a study of Mendelian randomization analysis.

Zhang N, Yue W, Jiao B, Cheng D, Wang J, Liang F Infect Agent Cancer. 2025; 20(1):9.

PMID: 39920741 PMC: 11806682. DOI: 10.1186/s13027-025-00640-8.


Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations.

Abecunas C, Kidd A, Jiang Y, Zong H, Fallahi-Sichani M Cell Rep. 2024; 43(10):114775.

PMID: 39305483 PMC: 11511630. DOI: 10.1016/j.celrep.2024.114775.


Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations.

Abecunas C, Kidd A, Jiang Y, Zong H, Fallahi-Sichani M bioRxiv. 2023; .

PMID: 38076921 PMC: 10705426. DOI: 10.1101/2023.11.28.569098.


Identifying essential genes in genome-scale metabolic models of consensus molecular subtypes of colorectal cancer.

Cheng C, Lai J, Chang P, Hong Y, Huang C, Wang F PLoS One. 2023; 18(5):e0286032.

PMID: 37205704 PMC: 10198572. DOI: 10.1371/journal.pone.0286032.


Metabolic profiling reveals metabolic features of consolidation therapy in pediatric acute lymphoblastic leukemia.

Fu J, Zhang A, Liu Q, Li D, Wang X, Si L Cancer Metab. 2023; 11(1):2.

PMID: 36691092 PMC: 9869545. DOI: 10.1186/s40170-023-00302-6.


References
1.
Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M . Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2013; 42(Database issue):D199-205. PMC: 3965122. DOI: 10.1093/nar/gkt1076. View

2.
Han K, Pierce S, Li A, Spees K, Anderson G, Seoane J . CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature. 2020; 580(7801):136-141. PMC: 7368463. DOI: 10.1038/s41586-020-2099-x. View

3.
Joly J, Delfarah A, Phung P, Parrish S, Graham N . A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020; 295(5):1350-1365. PMC: 6996897. DOI: 10.1074/jbc.RA119.011471. View

4.
SHEFER S, Tint G, Daikhin E, Kendler A, Nguyen L, Yudkoff M . Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?. J Neurosci Res. 2000; 61(5):549-63. DOI: 10.1002/1097-4547(20000901)61:5<549::AID-JNR10>3.0.CO;2-0. View

5.
Barbie D, Tamayo P, Boehm J, Kim S, Moody S, Dunn I . Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462(7269):108-12. PMC: 2783335. DOI: 10.1038/nature08460. View